Non-coding RNAs in drug and radiation resistance of bone and soft tissue sarcoma: a systematic review

  1. Huan-Huan Chen
  2. Tie-Ning Zhang
  3. Fang-Yuan Zhang  Is a corresponding author
  4. Tao Zhang  Is a corresponding author
  1. China Medical University, China

Abstract

Background: Sarcomas comprise approximately 1% of all human malignancies; treatment resistance is one of the major reasons for the poor prognosis of sarcomas. Accumulating evidence suggests that non-coding RNAs, including microRNAs, long non-coding RNAs, and circular RNAs, are important molecules involved in the crosstalk between resistance to chemotherapy, targeted therapy, and radiotherapy via various pathways.

Methods: We searched the PubMed (MEDLINE) database for articles regarding sarcoma-associated non-coding RNAs from inception to August17, 2022. Studies investigating the roles of host-derived microRNAs, long non-coding RNAs, and circular RNAs in sarcoma were included. Data regarding the roles of ncRNAs in therapeutic regulation and their applicability as biomarkers for predicting therapeutic response of sarcomas were extracted. Two independent researchers assessed the quality of the studies using Würzburg Methodological Quality Score(W-MeQS).

Results: Observational studies revealed ectopic expression of non-coding RNAs in sarcoma patients with different responses to antitumor treatments. Experimental studies have confirmed crosstalk between cellular pathways pertinent to chemotherapy, targeted therapy, and radiotherapy resistance. Of the included studies, W-MeQS scores ranged from 3 to 10 (average score = 5.42). Of the twelve articles that investigated non-coding RNAs as biomarkers, none included a validation cohort. Selective reporting of the sensitivity, specificity, and receiver operating curves was common.

Conclusion: Although non-coding RNAs appear to be good candidates as biomarkers for predicting treatment response and therapeutics for sarcoma, their differential expression across tissues complicates their application. Further research regarding their potential for inhibiting or activating these regulatory molecules to reverse treatment resistance may be useful.

Funding: This study's literature retrieval cost was supported by the 345 Talent Project of Shengjing Hospital of China Medical University(M0949 to Tao Zhang).

Data availability

All data generated or analysed during this study are included in the manuscript and supporting file. The data has also been deposited to Dryad

The following data sets were generated
    1. Zhang T
    2. Chen H
    3. Zhang T
    4. Zhang F
    (2022) 212 orginal articles
    Dryad Digital Repository, doi:10.5061/dryad.kd51c5b8t.

Article and author information

Author details

  1. Huan-Huan Chen

    Department of Oncology, China Medical University, Shenyang, China
    Competing interests
    The authors declare that no competing interests exist.
  2. Tie-Ning Zhang

    Department of Pediatrics, China Medical University, Shenyang, China
    Competing interests
    The authors declare that no competing interests exist.
  3. Fang-Yuan Zhang

    Department of General Surgery, China Medical University, Shenyang, China
    For correspondence
    fyzhang@cmu.edu.cn
    Competing interests
    The authors declare that no competing interests exist.
  4. Tao Zhang

    Department of Pediatrics, China Medical University, Shenyang, China
    For correspondence
    zhangtaocmu7@126.com
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5341-8249

Funding

345 Talent of Shengjing Hospital of China Medical University

  • Tao Zhang

The funder supported the data collection for the study.

Copyright

© 2022, Chen et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 514
    views
  • 73
    downloads
  • 4
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Huan-Huan Chen
  2. Tie-Ning Zhang
  3. Fang-Yuan Zhang
  4. Tao Zhang
(2022)
Non-coding RNAs in drug and radiation resistance of bone and soft tissue sarcoma: a systematic review
eLife 11:e79655.
https://doi.org/10.7554/eLife.79655

Share this article

https://doi.org/10.7554/eLife.79655

Further reading

    1. Cancer Biology
    Han V Han, Richard Efem ... Richard Z Lin
    Research Article

    Most human pancreatic ductal adenocarcinoma (PDAC) are not infiltrated with cytotoxic T cells and are highly resistant to immunotherapy. Over 90% of PDAC have oncogenic KRAS mutations, and phosphoinositide 3-kinases (PI3Ks) are direct effectors of KRAS. Our previous study demonstrated that ablation of Pik3ca in KPC (KrasG12D; Trp53R172H; Pdx1-Cre) pancreatic cancer cells induced host T cells to infiltrate and completely eliminate the tumors in a syngeneic orthotopic implantation mouse model. Now, we show that implantation of Pik3ca−/− KPC (named αKO) cancer cells induces clonal enrichment of cytotoxic T cells infiltrating the pancreatic tumors. To identify potential molecules that can regulate the activity of these anti-tumor T cells, we conducted an in vivo genome-wide gene-deletion screen using αKO cells implanted in the mouse pancreas. The result shows that deletion of propionyl-CoA carboxylase subunit B gene (Pccb) in αKO cells (named p-αKO) leads to immune evasion, tumor progression, and death of host mice. Surprisingly, p-αKO tumors are still infiltrated with clonally enriched CD8+ T cells but they are inactive against tumor cells. However, blockade of PD-L1/PD1 interaction reactivated these clonally enriched T cells infiltrating p-αKO tumors, leading to slower tumor progression and improve survival of host mice. These results indicate that Pccb can modulate the activity of cytotoxic T cells infiltrating some pancreatic cancers and this understanding may lead to improvement in immunotherapy for this difficult-to-treat cancer.

    1. Cancer Biology
    2. Immunology and Inflammation
    Almudena Mendez-Perez, Andres M Acosta-Moreno ... Esteban Veiga
    Short Report

    In this study, we present a proof-of-concept classical vaccination experiment that validates the in silico identification of tumor neoantigens (TNAs) using a machine learning-based platform called NAP-CNB. Unlike other TNA predictors, NAP-CNB leverages RNA-seq data to consider the relative expression of neoantigens in tumors. Our experiments show the efficacy of NAP-CNB. Predicted TNAs elicited potent antitumor responses in mice following classical vaccination protocols. Notably, optimal antitumor activity was observed when targeting the antigen with higher expression in the tumor, which was not the most immunogenic. Additionally, the vaccination combining different neoantigens resulted in vastly improved responses compared to each one individually, showing the worth of multiantigen-based approaches. These findings validate NAP-CNB as an innovative TNA identification platform and make a substantial contribution to advancing the next generation of personalized immunotherapies.